Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,315 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
How did FLGT's recent EPS compare to expectations?
The most recent EPS for Fulgent Genetics Inc is $-0.36, beating expectations of $-0.1.
How did Fulgent Genetics Inc FLGT's revenue perform in the last quarter?
Fulgent Genetics Inc revenue for the last quarter is $-0.36
What is the revenue estimate for Fulgent Genetics Inc?
According to 4 of Wall street analyst, the revenue estimate of Fulgent Genetics Inc range from $98.7M to $87.73M
What's the earning quality score for Fulgent Genetics Inc?
Fulgent Genetics Inc has a earning quality score of B+/56.791653. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Fulgent Genetics Inc report earnings?
Fulgent Genetics Inc next earnings report is expected in 2026-07-30
What are Fulgent Genetics Inc's expected earnings?
Fulgent Genetics Inc expected earnings is $69.45M, according to wall-street analysts.
Did Fulgent Genetics Inc beat earnings expectations?
Fulgent Genetics Inc recent earnings of $71.13M beat expectations.